Consistently, in melanoma patients under immunotherapy, we found that Th17 cells are reduced in the blood of subjects developing vitiligo compared to those not developing the irAE and that IL-17A-expressing cells are enriched in skin biopsy of immunotherapy-mediated vitiligo compared to the spontaneous disease. Here, IL17A is linked to vitiligo.